Drugs / SGN-CD228A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04042480 | Sep 2019 → Mar 2023 | Her2-receptor negative breast cancer, colorectal cancer, cutaneous melanoma, non-small cell lung carcinoma +2 | Seagen Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGN-CD228A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04042480 ↗ |
| Route | Intravenous | “SGN-CD228A administered into the vein (IV; intravenously)” NCT04042480 ↗ |
| Target | MELTF | “SGN-CD228A is an investigational antibody-drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97)” PMID 36800443 ↗ Apr 2023 |